계명대학교 의학도서관 Repository

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease

Metadata Downloads
Author(s)
Ji Yeon LeeJee Young LeeJae-Hoon Ko3Miri HyunHyun Ah KimSeongcheol ChoYong Dae LeeJunghoon SongSeunghwan ShinKyong Ran Peck
Keimyung Author(s)
Lee, Ji YeonHyun, Mi RiKim, Hyun Ah
Department
Dept. of Internal Medicine (내과학)
Journal Title
Front Immunol
Issued Date
2021
Volume
12
Keyword
Regdanvimabmonoclonal antibodyCOVID-19progressionoutcome
Abstract
Objective:
To evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent for treating coronavirus 2019 (COVID-19).

Methods:
A retrospective cohort study was conducted at two general hospitals during the study period of December 2020 to May 2021. Mild COVID-19 patients with risk factors for disease progression admitted to the hospitals within seven days of symptom onset were enrolled and followed until discharge or referral. Multivariate analyses for disease progression were conducted in the total and propensity score (PS)-matched cohorts.

Results:
A total of 778 mild COVID-19 patients were included and classified as the regdanvimab (n = 234) and supportive care (n = 544) groups. Significantly fewer patients required O2 supplementation via nasal prong in the regdanvimab group (8.1%) than in the supportive care group (18.4%, P < 0.001). The decreased risk for O2 support by regdanvimab treatment was noticed in the multivariate analysis of the total cohort (HR 0.570, 95% CI 0.343–0.946, P = 0.030), but it was not statistically significant in the PS-matched cohort (P = 0.057). Progression to severe disease was also significantly lower in the regdanvimab group (2.1%) than in the supportive care group (9.6%, P < 0.001). The significantly reduced risk for progression to severe disease by regdanvimab treatment was observed in the analysis of both the total cohort (HR 0.262, 95% CI 0.103–0.667, P = 0.005) and PS-matched cohort (HR 0.176, 95% CI 0.060–0.516, P = 0.002). Potential risk factors for progression were investigated in the supportive care group and SpO2 < 97% and CRP elevation >1.5 mg/dL were common risk factors for O2 support and progression to severe disease. Among the patients with any of these factors, regdanvimab treatment was associated with decreased risk for progression to severe disease with slightly lower HR (HR 0.202, 95% CI 0.062–0.657, P = 0.008) than that of the total cohort.

Conclusion:
Regdanvimab treatment was associated with a decreased risk of progression to severe disease.
Keimyung Author(s)(Kor)
이지연
현미리
김현아
Publisher
School of Medicine (의과대학)
Citation
Ji Yeon Lee et al. (2021). Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease. Front Immunol, 12, 772320. doi: 10.3389/fimmu.2021.772320
Type
Article
ISSN
1664-3224
Source
https://www.frontiersin.org/articles/10.3389/fimmu.2021.772320/full
DOI
10.3389/fimmu.2021.772320
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44120
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.